Exelixis, Inc., is a biotechnology company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources, development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company’s programs include: COMETRIQ, Cobimetinib Collaboration, and Other Collaborations. COMETRIQ, potential active anti-cancer agent and treats progressive, metastatic MTC and has therapeutic potential, as well as inhibits the activity of multiple tyrosine kinases, including RET, MET, and VEGFR2. Cobimetinib Collaboration, co-development agreement for the development and commercialization of cobimetinib which is an inhibitor of MEK, a serine threonine kinase. Other Collaborations, has established collaborations with pharmaceutical and biotechnology companies for compounds and programs.